Skip to content

To keep going please Log in.

or

By submitting my information, I agree to the Privacy Policy and Terms of Service.

To keep going please Log in.

or

By submitting my information, I agree to the Privacy Policy and Terms of Service.

To keep going please Log in.

or

By submitting my information, I agree to the Privacy Policy and Terms of Service.

To keep going please Log in.

or

By submitting my information, I agree to the Privacy Policy and Terms of Service.

CYTK Cytokinetics Inc.
$63.48 -0.43% -0.27
Notify me if price changes either direction
Interactive Brokers Logotype

Buy CYTK stocks now with Interactive Brokers – the most advanced investment platform

Contents
  • Performance
  • Key stats
  • Financials
  • US politician trades
Loading

Key Stats

Market cap. 7.7B
Enterprise value 8.1B
Trailing PE -12.007604533729
Forward PE -10.666105
PEG Ratio -0.13722976609975
Enterprise to EBITDA -14.452
Enterprise to revenue 93.343
Price to book MRQ -14.541793591325
Price to sales TTM 88.89726

Financials

Fiscal Year Ends 2024-12-31
Most Recent Quarter (MRQ) 2025-09-30
Revenue (TTM) 87.2M
EBITDA -563284992
Diluted EPS TTM -6.3
Total Cash (MRQ) 962.5M
Current ratio (MRQ) 6.876
Operating Cash Flow (TTM) -432928000

CYTK trades by the US politicians

Percentage
0% 0 sells
100% 0 buys
Amount
$0 0 sells
$0 0 buys
In the last 0 months

Recent CYTK News

Home

IMPORTANT NOTICE

Finbold is a news and information website. This Site may contain sponsored content, advertisements, and third-party materials, for which Finbold expressly disclaims any liability.

RISK WARNING: Cryptocurrencies are high-risk investments and you should not expect to be protected if something goes wrong. Don’t invest unless you’re prepared to lose all the money you invest. (Click here to learn more about cryptocurrency risks.)

By accessing this Site, you acknowledge that you understand these risks and that Finbold bears no responsibility for any losses, damages, or consequences resulting from your use of the Site or reliance on its content. Click here to learn more.